Logo image of CKPT

CHECKPOINT THERAPEUTICS INC (CKPT) Stock Fundamental Analysis

NASDAQ:CKPT - Nasdaq - US1628282063 - Common Stock - Currency: USD

4.26  +0.03 (+0.71%)

After market: 4.2705 +0.01 (+0.25%)

Fundamental Rating

1

CKPT gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. Both the profitability and financial health of CKPT have multiple concerns. CKPT has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CKPT has reported negative net income.
CKPT had a negative operating cash flow in the past year.
In the past 5 years CKPT always reported negative net income.
In the past 5 years CKPT always reported negative operating cash flow.
CKPT Yearly Net Income VS EBIT VS OCF VS FCFCKPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of CKPT (-752.78%) is worse than 97.67% of its industry peers.
Industry RankSector Rank
ROA -752.78%
ROE N/A
ROIC N/A
ROA(3y)-729.34%
ROA(5y)-468.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CKPT Yearly ROA, ROE, ROICCKPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500

1.3 Margins

CKPT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CKPT Yearly Profit, Operating, Gross MarginsCKPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

0

2. Health

2.1 Basic Checks

CKPT has more shares outstanding than it did 1 year ago.
CKPT has more shares outstanding than it did 5 years ago.
CKPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CKPT Yearly Shares OutstandingCKPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CKPT Yearly Total Debt VS Total AssetsCKPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -85.21, we must say that CKPT is in the distress zone and has some risk of bankruptcy.
CKPT has a worse Altman-Z score (-85.21) than 96.42% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -85.21
ROIC/WACCN/A
WACCN/A
CKPT Yearly LT Debt VS Equity VS FCFCKPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 0.37 indicates that CKPT may have some problems paying its short term obligations.
CKPT has a worse Current ratio (0.37) than 93.74% of its industry peers.
CKPT has a Quick Ratio of 0.37. This is a bad value and indicates that CKPT is not financially healthy enough and could expect problems in meeting its short term obligations.
CKPT has a worse Quick ratio (0.37) than 93.20% of its industry peers.
Industry RankSector Rank
Current Ratio 0.37
Quick Ratio 0.37
CKPT Yearly Current Assets VS Current LiabilitesCKPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

CKPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.43%, which is quite impressive.
The Revenue for CKPT has decreased by -60.19% in the past year. This is quite bad
Measured over the past years, CKPT shows a very negative growth in Revenue. The Revenue has been decreasing by -52.58% on average per year.
EPS 1Y (TTM)53.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.42%
Revenue 1Y (TTM)-60.19%
Revenue growth 3Y-46.65%
Revenue growth 5Y-52.58%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CKPT will show a very strong growth in Earnings Per Share. The EPS will grow by 31.84% on average per year.
Based on estimates for the next years, CKPT will show a very strong growth in Revenue. The Revenue will grow by 711.65% on average per year.
EPS Next Y87.52%
EPS Next 2Y67.51%
EPS Next 3Y85.74%
EPS Next 5Y31.84%
Revenue Next Year300659%
Revenue Next 2Y11555.7%
Revenue Next 3Y3960.1%
Revenue Next 5Y711.65%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CKPT Yearly Revenue VS EstimatesCKPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CKPT Yearly EPS VS EstimatesCKPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CKPT. In the last year negative earnings were reported.
CKPT is valuated cheaply with a Price/Forward Earnings ratio of 3.70.
98.57% of the companies in the same industry are more expensive than CKPT, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of CKPT to the average of the S&P500 Index (37.64), we can say CKPT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.7
CKPT Price Earnings VS Forward Price EarningsCKPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CKPT Per share dataCKPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CKPT's earnings are expected to grow with 85.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.51%
EPS Next 3Y85.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CKPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHECKPOINT THERAPEUTICS INC

NASDAQ:CKPT (5/29/2025, 8:00:00 PM)

After market: 4.2705 +0.01 (+0.25%)

4.26

+0.03 (+0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11
Inst Owners37.08%
Inst Owner Change-2.17%
Ins Owners0.2%
Ins Owner Change-4505.02%
Market Cap370.71M
Analysts77.78
Price Target4.42 (3.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-154.89%
Min EPS beat(2)-256.04%
Max EPS beat(2)-53.74%
EPS beat(4)1
Avg EPS beat(4)-71.5%
Min EPS beat(4)-256.04%
Max EPS beat(4)42.14%
EPS beat(8)3
Avg EPS beat(8)-41.96%
EPS beat(12)5
Avg EPS beat(12)-34.73%
EPS beat(16)6
Avg EPS beat(16)-35.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-63.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.7
P/S 9041.59
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)1.15
Fwd EY27.06%
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0
BVpS-0.15
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -752.78%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-729.34%
ROA(5y)-468.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.37
Quick Ratio 0.37
Altman-Z -85.21
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.42%
EPS Next Y87.52%
EPS Next 2Y67.51%
EPS Next 3Y85.74%
EPS Next 5Y31.84%
Revenue 1Y (TTM)-60.19%
Revenue growth 3Y-46.65%
Revenue growth 5Y-52.58%
Sales Q2Q%N/A
Revenue Next Year300659%
Revenue Next 2Y11555.7%
Revenue Next 3Y3960.1%
Revenue Next 5Y711.65%
EBIT growth 1Y-7.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.65%
OCF growth 3YN/A
OCF growth 5YN/A